3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
70
Breast Neoplasms
52
Ovarian Neoplasms
43
Lung Neoplasms
24
Neoplasms
21
Neoplasm Metastasis
20
Fallopian Tube Neoplasms
20
Carcinoma, Ovarian Epithelial
18
Triple Negative Breast Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Uterine Cervical Neoplasms
9
Head and Neck Neoplasms
9
Stomach Neoplasms
8
Recurrence
8
Endometrial Neoplasms
8
Adenocarcinoma of Lung
8
Melanoma
7
Esophageal Neoplasms
6
Urinary Bladder Neoplasms
5
Pancreatic Neoplasms
5
Uterine Neoplasms
4
Solid Tumors
4
Small Cell Lung Carcinoma
4
Prostatic Neoplasms
4
Adenocarcinoma, Bronchiolo-Alveolar
4
Adenocarcinoma Of Esophagus
4
Thoracic Neoplasms
3
Testicular Neoplasms
3
Solid Tumor
3
Sarcoma
3
Interventions
pembrolizumab
1
bemarituzumab
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Squamous-Cell Non-Small-Cell Lung Cancer
×
Paclitaxel
×
Clear all
NCT05267470
2025-03-25
FORTITUDE-201
Amgen
Phase 1
Terminated
74 enrolled
22 charts